1. Home
  2. NP vs ACAD Comparison

NP vs ACAD Comparison

Compare NP & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neptune Insurance Holdings Inc.

NP

Neptune Insurance Holdings Inc.

HOLD

Current Price

$32.26

Market Cap

4.4B

Sector

Finance

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$25.51

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NP
ACAD
Founded
2017
1993
Country
United States
United States
Employees
60
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
3.8B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
NP
ACAD
Price
$32.26
$25.51
Analyst Decision
Buy
Buy
Analyst Count
12
22
Target Price
$28.17
$30.55
AVG Volume (30 Days)
987.4K
1.9M
Earning Date
04-22-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
N/A
0.02
Revenue
N/A
$726,437,000.00
Revenue This Year
$25.84
$18.80
Revenue Next Year
$15.80
$11.70
P/E Ratio
N/A
$1,311.00
Revenue Growth
N/A
40.45
52 Week Low
$14.78
$19.69
52 Week High
$34.61
$28.35

Technical Indicators

Market Signals
Indicator
NP
ACAD
Relative Strength Index (RSI) 59.30 63.34
Support Level $23.62 $25.40
Resistance Level N/A $27.79
Average True Range (ATR) 1.71 0.92
MACD 0.08 0.12
Stochastic Oscillator 68.43 64.91

Price Performance

Historical Comparison
NP
ACAD

About NP Neptune Insurance Holdings Inc.

Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: